Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ginkgo Bioworks Holdings, Inc. Class A Common Stock (NY:DNA)

10.20 +0.19 (+1.90%)
Streaming Delayed Price Updated: 3:04 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ginkgo Bioworks Holdings, Inc. Class A Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Why Ginkgo Bioworks Shares Are Rising After Announcement With Partner Cronos Group
Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 7.63% to $2.68 after the company, and Cronos Group Inc (NASDAQ: CRON), announced the achievement of the third target productivity... 
Via Benzinga
Cronos Group And Ginkgo Bioworks Achieve Rare Cannabinoid THCV Equity Milestone
Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) and Ginkgo Bioworks (NYSE: DNA) achieved the third target productivity milestone in their partnership 
Via Benzinga
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Cathie Wood Is Selling Gene Editing Stocks. Here’s Why.
Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves? 
Via InvestorPlace
Cathie Wood Keeps Buying Gingko Bioworks (DNA) Stock
Shares of DNA stock are in focus following Ark Invest's buying spree this month. In the past two days, Ark has purchased 4.5 million shares. 
Via InvestorPlace
Losing Money Is in Ginkgo Bioworks Holdings’ DNA
DNA stock is a falling knife in 2022, and the latest earnings do not justify being optimistic about reaching profitability soon. 
Via InvestorPlace
Why Ginkgo Bioworks Stock Is Falling After Hours
Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading lower in Monday's after-hours session after the company 
Via Benzinga
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
Via Benzinga
74 Biggest Movers From Yesterday
Gainers 
Via Benzinga
ADSK Stock Sinks 8% Following Analyst Downgrade
Autodesk (ADSK) stock is slipping on Monday after getting hit with a downgrade and price target drop from Deutsche Bank analyst Bhavin Shah. 
Via InvestorPlace
Why Is Ginkgo Bioworks (DNA) Stock Up Today?
Biotechnology company Ginkgo Bioworks has a host of promising collaboration announcements. DNA stock is up as a result. 
Via InvestorPlace
Benzinga Bulls And Bears Of The Week: Netflix, Coinbase, Apple, Rivian And A Biotech Scooped Up By Cathie Wood
Benzinga has examined the prospects for many investor favorite stocks over the past week, while offering a 24/7 news feed, live chat and charting software on Benzinga Pro. 
Via Benzinga
Tesla Bull Cathie Wood Scoops Up $11.5M In Bill Gates-Backed Biotech's Stock
Ark Investment Management, led by Tesla Inc. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022
 
Via Benzinga
BofA Downgrades Ginkgo Bioworks, Cuts Price Target In Half
While Ginkgo Bioworks Holdings Inc’s (NYSE: DNA) overall first-quarter results were better than expected, revenues and active programs in its core Foundry segment fell short of estimates, according to... 
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Down Over 1%; Jumia Technologies Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 200 points on Tuesday. 
Via Benzinga
Looking Into Ginkgo Bioworks Holdings's Recent Short Interest
Ginkgo Bioworks Holdings's (NYSE:DNA) short percent of float has risen 9.65% since its last report. The company recently reported that it has 81.30 million shares sold short,... 
Via Benzinga
7 Growth Stocks to Buy on the Dip
Although the wave of red ink in the major indices is intimidating, it also presents an intriguing opportunity for growth stocks to buy. 
Via InvestorPlace
Cathie Wood Keeps Buying Gingko Bioworks (DNA) Stock. Here’s Why.
DNA stock is in the spotlight after Ark Invest reported purchasing more than 1.5 million shares this week. So, who else is betting big on Ginkgo? 
Via InvestorPlace
7 Biggest Loser Stocks That Could Become Surprising Buys
A huge pouring of red ink can sometimes lead to extraordinary gains, though you’ve got to be aware of the risks. 
Via InvestorPlace
28 Biggest Movers From Yesterday
Gainers HighPeak Energy, Inc. (NASDAQ: HPK) shares gained 31.76% to close at $28.83 on Wednesday, after CNBC’s Jim Cramer said the mid-cap company is an aggressive play on... 
Via Benzinga
NYSE:DNA Long Term Investor Alert: Investigation of Potential Wrongdoing at Ginkgo Bioworks Holdings, Inc.
San Diego, CA -- (SBWIRE) -- 04/13/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Ginkgo Bioworks Holdings, Inc. 
Via SBWire
Elanco, Ginkgo Bioworks Launch BiomEdit, Microbiome-Focused Animal Health Firm
Elanco Animal Health Incorporated (NYSE: ELAN) and Ginkgo Bioworks Holdings Inc (NYSE: DNA) have launched BiomEdit, a microbiome innovation company.... 
Via Benzinga
Baillie Gifford Just Bought Ginkgo Bioworks (DNA) Stock. Here’s Why.
Baillie Gifford recently disclosed that it purchased 48.8 million shares of DNA stock on March 31. The firm has a $180 billion portfolio. 
Via InvestorPlace
Twist Bioscience and Ginkgo Bioworks Sign New Collaboration
From Twist Bioscience Corporation
Via Business Wire
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) jumped 88.1% to $0.38 after declining 9% on Monday. McCormick (NASDAQ: IGMS) shares jumped 49.8% to $22.46. Sanofi SA (... 
Via Benzinga
53 Biggest Movers From Yesterday
Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) shares gained 96.7% to settle at $29.49 on Tuesday. Sanofi SA (NASDAQ: SNY) and IGM Biosciences signed an exclusive worldwide... 
Via Benzinga
Here's Why Ginkgo Bioworks Shares Are Rising
Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 22.0% at $4.56 after the company reported better-than-expected fourth-quarter sales results and issued FY22 sales guidance above... 
Via Benzinga
Is DNA Stock a Buy After Earnings? 3 Analysts Weigh In on Gingko Bioworks.
DNA stock is bouncing higher following a better-than-expected earnings report and strong forward guidance from Gingko Bioworks. 
Via InvestorPlace
8 Materials Stocks Moving In Tuesday's Pre-Market Session
Gainers Ginkgo Bioworks Holdings (NYSE:DNA) shares rose 9.9% to $4.11 during Tuesday's pre-market session. The market value of their outstanding shares is at $6.8 billion. The company's, Q4 earnings... 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.